AUSTEDO: Demonstrated safety and tolerability profile in Huntington’s disease (HD) chorea patients1-3

Adverse Events Reported in ≥4% of Patients Treated With AUSTEDO in Placebo-Controlled Studies

Adverse events reported in ≥4% of patients treated with AUSTEDO in placebo-controlled studies. Adverse events reported in ≥4% of patients treated with AUSTEDO in placebo-controlled studies.

Rates of discontinuation and dose reduction due to adverse events were similar across study arms1,3

  • Discontinuation due to adverse events occurred in 2% of patients in both the AUSTEDO and placebo arms
  • Dose reduction due to adverse events was required in 7% of patients in both the AUSTEDO and placebo arms

Some adverse events were not reported once patients reached their maintenance dose2:

  • Somnolence
  • Dry mouth
  • Diarrhea
  • Diarrhea
  • Dry mouth
  • Fatigue
  • Adverse events of special interest, including parkinsonism, akathisia, restlessness, and suicidal ideation, were not reported in any patients during titration phase and were reported in ≤4% of patients in both arms during maintenance phase2
  • Anxiety was reported in ≤4% of patients in both arms during titration and maintenance phases2

REFERENCES: 1. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information. Parsippany, NJ, Teva Neuroscience, Inc. 2. Data on file. North Wales, PA: Teva Neuroscience, Inc. 3. Frank S, Testa CM, Stamler D, et al.; Huntington Study Group. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA. 2016;316(1):40-50.